Attachment
The biomarker market was worth $5.5bn in 2007 and is forecast to grow at a CAGR of 17.6% to $12.4b in 2012 - Business Insights, 2008. The development and application of biomarkers have become an increasingly important topic for the pharma/biotech companies.
Biomarkers are not only used as the valuable tools in the early development stages in the lifecycle of a new drug but they also play a significant role after the drug is introduced in the market.
Our 2nd Annual Biomarkers Conference will provide an ideal platform for the attendees to get an overview of the biomarkers. This conference will enable you to identify and overcome the challenges in the specific therapeutic areas and understand the new developments and recent advancements in the field of biomarkers.
Reasons for attending the Conference:
Share and discuss the growth trends in the biomarkers
Get timely answers to the key questions about the role of biomarkers in drug development and clinical use
Identify the challenges in the specific therapeutic areas
Examine the biomarker data management and analysis
Understand the recent advancement in imaging modalities as biomarkers
Hear about the effective biomarker out- and in-licensing
Gain an insight into the commercial aspects in biomarkers
Discuss the latest biomarker assay developments and methods of clinical validation
Who will be there?
VPs, Directors, Heads and Managers of:
Biomarker Development Programmes
Clinical Pharmacology
Clinical Research
Drug Discovery and Development
Alliance Management
Safety Assessment
Assay Development
Proteomics/ Genomics Programmes
Regulatory Affairs
Translational Medicine
Oncology
CNS
Inflammation and Immunology
Biological Sciences
Marketing
Product
Diagnostics
Bioanalysis
Pharmacokinetics & Drug Metabolism
Genomics Business Development
Strategic Alliances
Cellular & Molecular Dev
Clinical Discovery Technologies
Pharmacogenomics & Human Genetics
Discovery Research
Bioengineering
Key Speakers
Dr Harsukh Parmar, Global Head of Early Clinical Development Respiratory & Inflammation Therapy Area, AstraZeneca
Dr Michael Binks, Head, Immuno-Epigenetics DPU Immuno-Inflammation CEDD, GlaxoSmithKline
Dr Jochen Theis, Owner and Principle Consultant, InHeCon - Jochen Theis & Associates
Dr Richard Kennedy, Vice President of Translational Research and Development, Almac Diagnostics
Dr Christian Czech, CNS Research, Roche
Dr Oliver Steinbach, Senior Director, Department Bio-Molecular Engineering, Philips Research
Dr Eddie Blair, Director, Integrated Medicines
Dr Timothy Ebbels, Lecturer in Computational Bioinformatics, Imperial College London
Dr Manuel Mayr, Lecturer, Cardiovascular Division, Kings College London
Dr Elke Roschmann, Senior Director Strategic Development & Licensing, Epidauros Biotechnologie
Prof K. K. Jain, CEO, PharmaBiotech
For more information kindly visit: http://www.bharatbook.com/
OR Contact us at
Bharat Book Bureau
207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com
Photo:
http://www.prlog.org/
